Quadrant Capital Group LLC Kinnate Biopharma Inc. Transaction History

Quadrant Capital Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$9.86 - $15.76 $2,277 - $3,640	-231 Reduced 35.05%	428 $5,000
Q2 2022 Aug 09, 2022	SELL	$7.43 - $13.0 $2,652 - $4,641	-357 Reduced 35.14%	659 $8,000
Q1 2022 May 06, 2022	BUY	$7.73 - $17.99 $4,243 - $9,876	549 Added 117.56%	1,016 $11,000
Q4 2021 Feb 01, 2022	BUY	$16.5 - $25.48 $7,342 - $11,338	445 Added 2022.73%	467 $8,000
Q3 2021 Nov 12, 2021	BUY	$17.81 - $24.87 $391 - $547	22 New	22 $1,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.